Severine Vermeire
Appearances
- DateMay 7, 2023There are multiple new biologic agents that have been approved for the management of IBD over the past few years. In addition, high quality randomized controlled trials have examined optimization of these treatments through therapeutic drug monitoring…
Presenter
- DateMay 7, 2023There are multiple new biologic agents that have been approved for the management of IBD over the past few years. In addition, high quality randomized controlled trials have examined optimization of these treatments through therapeutic drug monitoring…
Presenters
University of PennsylvaniaUniversity of Chicago Division of the Biological Sciences - DateMay 7, 2023The pathogenesis of inflammatory bowel disease (IBD) involves crosstalk between genetic and microbial factors that influence immune reactions. Tofacitinib, a pan JAK-STAT inhibitor, is a small molecule indicated for the treatment of moderate-to-severe ulcerative colitis (UC)…
Presenter
Speakers
University Hospitals LeuvenIcahn School of Medicine at Mount SinaiIcahn School of Medicine at Mount SinaiIcahn School of Medicine at Mount Sinai - DateMay 7, 2023Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
Presenter
Speakers
University of Chicago Division of the Biological SciencesWestern UniversityCedars-Sinai Medical Center
